Search research articles
Contact Us
Filters
Showing results (31-40 of 56) with videos related to
Page
of 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2003
Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial
Mace L Rothenberg, P Y Liu, Patricia S Braly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2005
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma
Mace L Rothenberg, Bonnie LaFleur, Donna E Levy, et al.
American Journal of Clinical Oncology
|
April 8, 2006
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer
Albert Craig Lockhart, Gillian F Cropp, Jordan D Berlin, et al.
The Oncologist
|
May 27, 2018
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action
Tomas G Neilan, Mace L Rothenberg, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2008
TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer
Nipun B Merchant, Igor Voskresensky, Christopher M Rogers, et al.
Nature Reviews. Clinical Oncology
|
October 3, 2018
Accelerating anticancer drug development - opportunities and trade-offs
Sharyl J Nass, Mace L Rothenberg, Rebecca Pentz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2011
Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors
Igor Puzanov, Wooin Lee, Alice P Chen, et al.
Cancer Chemotherapy and Pharmacology
|
September 4, 2012
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors
Jeffrey R Infante, Vicki L Keedy, Suzanne F Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2004
A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors
A Craig Lockhart, Martin Howard, Kenneth R Hande, et al.
Cancer Chemotherapy and Pharmacology
|
May 21, 2005
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors
Hiroyuki Kobayashi, S Gail Eckhardt, Jennifer A Lockridge, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 56) with videos related to
Sort By:
Page
of 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2003
Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial
Mace L Rothenberg, P Y Liu, Patricia S Braly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2005
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma
Mace L Rothenberg, Bonnie LaFleur, Donna E Levy, et al.
American Journal of Clinical Oncology
|
April 8, 2006
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer
Albert Craig Lockhart, Gillian F Cropp, Jordan D Berlin, et al.
The Oncologist
|
May 27, 2018
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action
Tomas G Neilan, Mace L Rothenberg, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2008
TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer
Nipun B Merchant, Igor Voskresensky, Christopher M Rogers, et al.
Nature Reviews. Clinical Oncology
|
October 3, 2018
Accelerating anticancer drug development - opportunities and trade-offs
Sharyl J Nass, Mace L Rothenberg, Rebecca Pentz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2011
Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors
Igor Puzanov, Wooin Lee, Alice P Chen, et al.
Cancer Chemotherapy and Pharmacology
|
September 4, 2012
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors
Jeffrey R Infante, Vicki L Keedy, Suzanne F Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2004
A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors
A Craig Lockhart, Martin Howard, Kenneth R Hande, et al.
Cancer Chemotherapy and Pharmacology
|
May 21, 2005
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors
Hiroyuki Kobayashi, S Gail Eckhardt, Jennifer A Lockridge, et al.
Page
of 6